Jeffrey T. L. Smith
Known title: EVP & Chief Medical OfficerCIK: 0001604800
Associated companies
Transaction History
| ZYME | ▲ Buy | Option Exercise | 17,666 | $0 | 1/12/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 9,310 | $211K | 1/12/2026 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 20,000 | $0 | 1/5/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 10,538 | $264K | 1/5/2026 | View on chart |
| ZYME | ▼ Sell | Open Market | 11,110 | $166K | 1/6/2025 | View on chart |
| ZYME | ▲ Buy | Option Exercise | 20,000 | $0 | 1/6/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZYME News Highlights Potential Undervaluation and Raised Price Target
Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.
ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.